Wealth Enhancement Advisory Services LLC Has $207,000 Position in Immunome, Inc. $IMNM

Wealth Enhancement Advisory Services LLC decreased its position in Immunome, Inc. (NASDAQ:IMNM) by 66.8% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 17,660 shares of the company’s stock after selling 35,527 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Immunome were worth $207,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Immunome by 44.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after buying an additional 14,398 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Immunome in the second quarter worth $428,000. Private Capital Advisors Inc. lifted its position in Immunome by 393.1% during the 2nd quarter. Private Capital Advisors Inc. now owns 189,844 shares of the company’s stock worth $1,766,000 after buying an additional 151,343 shares in the last quarter. Brighton Jones LLC acquired a new position in shares of Immunome during the 2nd quarter worth about $98,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Immunome in the second quarter valued at about $793,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Performance

IMNM opened at $23.41 on Thursday. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $27.65. The company has a market capitalization of $2.58 billion, a P/E ratio of -7.94 and a beta of 2.32. The stock has a fifty day moving average of $22.39 and a 200-day moving average of $16.34.

Insiders Place Their Bets

In other Immunome news, insider Philip Tsai bought 10,000 shares of the stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $20.49 per share, with a total value of $204,900.00. Following the completion of the acquisition, the insider owned 43,300 shares of the company’s stock, valued at $887,217. This trade represents a 30.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Isaac Barchas sold 383,200 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have acquired a total of 68,518 shares of company stock worth $1,453,958 in the last quarter. Corporate insiders own 7.69% of the company’s stock.

Analyst Upgrades and Downgrades

IMNM has been the subject of several recent analyst reports. Truist Financial assumed coverage on Immunome in a report on Monday, December 1st. They issued a “buy” rating and a $36.00 price objective for the company. Leerink Partners set a $40.00 target price on shares of Immunome in a research note on Monday, December 15th. Wedbush reissued an “outperform” rating and set a $31.00 price target on shares of Immunome in a research report on Thursday, January 15th. Stephens raised their price objective on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, November 17th. Finally, Lake Street Capital boosted their target price on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.75.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.